NYSE:COV (COV) (COV) Stock Price, News & Analysis → My #1 investment for 2024 (From True Market Insiders) (Ad) Free COV Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume3.88 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get (COV) alerts: Email Address Ad True Market Insidersget a piece of the profit from this land This isn’t the prettiest land on earth. But it might be the most valuable. And you don’t have to own, lease, or rent any land.Click here to see my #1 investment for 2024. About (COV) Stock (NYSE:COV)Covidien Public Limited Company is a healthcare products company. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. The Company’s brands include Kendall, Nellcor, Puritan Bennett and Valleylab, among others. It has a presence in more than 70 countries, with products sold in over 150 countries. The Company’s segments include Medical Devices and United States Medical Supplies. Medical Devices includes marketing of advanced and general surgical solutions, peripheral vascular and neurovascular therapies, patient monitoring products, and airway and ventilation products. United States Medical Supplies includes products, such as nursing care, medical surgical, SharpSafety and original equipment manufacturer (OEM) products. The Company’s products include Surgical Solutions, Vascular Therapies, Respiratory and Patient Care.Read More Ad True Market Insidersget a piece of the profit from this land This isn’t the prettiest land on earth. But it might be the most valuable. And you don’t have to own, lease, or rent any land.Click here to see my #1 investment for 2024. COV Stock News HeadlinesMay 18 at 9:43 AM | msn.comRepeat COVID-19 vaccinations elicit antibodies that neutralize variants, other virusesMay 17 at 6:04 PM | msn.comCould a cup of tea keep Covid-19 at bay?May 17 at 1:03 PM | msn.comPandemic treaty talks in Geneva get one final big pushMay 17 at 8:03 AM | msn.comA new COVID-19 variant, FLiRT, could cause a summer surge. These are the symptoms.May 17 at 8:03 AM | msn.comPre-vaccine COVID-19: US study reveals hospitalization rate of 5.7% and fatality rate of 1.7%May 16 at 8:03 AM | theglobeandmail.comClosing Bell: CI Energy Giants Cov Call ETF flat on Friday (NXF)May 15 at 10:03 PM | msn.comCOVID-19 linked to rise in autoimmune lung disease, study findsMay 15 at 5:03 PM | msn.comNew COVID-19 'FLiRT' variants are now the dominant variant. Could there be a summer surge?May 15 at 9:55 AM | msn.comNew study identifies mechanism of immune evasion of SARS-CoV-2 and variantsMay 14, 2024 | msn.comStudy shows virus that causes COVID-19 can penetrate blood-retinal-barrier and could damage visionMay 14, 2024 | msn.comFinding the chink in coronavirus's armor—experiment reveals how the main protease of SARS-CoV-2 protects itselfMay 14, 2024 | msn.comCurcuminoid compounds show promise against COVID-19 in neuronal cellsMay 14, 2024 | msn.comCOVID-19 survivors show lasting brain function alterations, fMRI study findsMay 14, 2024 | yahoo.comFDA: Cue Health COVID tests may return false positive, negative results, throw them awayMay 14, 2024 | msn.comStudy Links Elevated CO2 Levels to Increased SARS-CoV-2 Aerosol TransmissionMay 14, 2024 | msn.comDeadly new Covid after-effect confirmed by scientistsMay 13, 2024 | msn.comGenetic analyses reveal new viruses on the horizonMay 12, 2024 | msn.comIf you’re the rare person who hasn’t had COVID, are you a super-dodger?May 11, 2024 | msn.comNew vaccine could protect against coronaviruses that haven't even emerged yetMay 11, 2024 | msn.comA deadly coronavirus has resurfaced in Saudi Arabia, killing at least one patientMay 9, 2024 | msn.com2 new COVID ‘FLiRT’ variants are on the rise: Watch out for these symptomsMay 9, 2024 | msn.comHow ‘Quartet Nanocage’ vaccine developed in Cambridge, Oxford and Caltech could provide broad protection against coronaviruses - including ones we don’t know exist yetMay 9, 2024 | msn.comNovel bispecific antibodies show promise against evolving SARS-CoV-2 variantsMay 8, 2024 | msn.comTeam develops computational approach to redesign antibodies for broader effectiveness against viral pandemicsMay 8, 2024 | msn.comAfrica: World Health Organization Advises Updated Vaccine Composition to Tackle SARS-CoV-2 EvolutionSee More Headlines Receive COV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for (COV) and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/05/2014Today5/18/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorN/A Industry N/A Sub-IndustryHealth Care Equipment Current SymbolNYSE:COV CUSIPG2554F11 CIK1385187 WebN/A Phone+353-1-4381700FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesGary L. Ellis (Age 61)President, Chief Executive Officer Charles J. Dockendorff (Age 63)Chief Financial Officer, Executive Vice President Bryan C. Hanson (Age 50)Group President, Covidien John H. Masterson (Age 54)Senior Vice President, General Counsel Michael P. Dunford (Age 54)Senior Vice President - Human Resources James C. Clemmer (Age 53)Senior Vice President and President - Medical Supplies Business Amy A. McBride-Wendell (Age 53)Senior Vice President - Strategy and Business Development Jacqueline F. Strayer (Age 58)Senior Vice President-Corporate Communications Michael E. Tarnoff (Age 46)Senior Vice President,Chief Medical Officer Peter L. Wehrly (Age 57)Senior Vice President, Group President - Developed Markets More Executives COV Stock Analysis - Frequently Asked Questions How were (COV)'s earnings last quarter? (COV) (NYSE:COV) posted its earnings results on Wednesday, November, 5th. The healthcare company reported $1.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.02 by $0.13. The healthcare company earned $2.73 billion during the quarter, compared to the consensus estimate of $2.69 billion. The business's quarterly revenue was up 6.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.91 earnings per share. What other stocks do shareholders of (COV) own? Based on aggregate information from My MarketBeat watchlists, some companies that other (COV) investors own include Pfizer (PFE), Chevron (CVX), Intel (INTC), Johnson & Johnson (JNJ), Boeing (BA), CVS Health (CVS), EMC (EMC), Gilead Sciences (GILD) and JPMorgan Chase & Co. (JPM). This page (NYSE:COV) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingObama’s Forever Term [exposed]Porter & Company4 Cryptos BETTER than BitcoinTrue Market InsidersElon’s New Device is About to Shock the WorldInvestorPlaceUrgent Nvidia WarningAltimetryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMissed NVDA? Buy this AI stock NOWChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (COV) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.